A+HA Premium Oral Hyaluronic Acid Drink Functional Evaluation Trial for Delaying Joint Pain

NCT07800676 | Not Yet Recruiting

• 1 other identifier: N202606002
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Evaluate the effect of A+HA premium oral hyaluronic acid drink on relieving knee pain.

Conditions

Knee Pain Chronic

Keywords

Knee pain; Hyaluronic acid; Chondroitin; Glucosamine hydrochloride

Outcome Measures

Primary Outcomes (2)

• Points change of pain evaluation scale

  Self-assess pain using a visual analog scale (VAS), which is a straight line 10 cm in length, with 0 cm on the left representing no pain and 10 cm on the right representing extreme pain. Explain to the subjects that the pain intensity increases from left to right. Ask the subjects to mark the point on the line that corresponds to their pain level, and then record the distance in centimeters from the 0 cm mark. Record the points that the subjects wrote.

  From the start to the end of treatment at 12 weeks

• Points change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

  Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a widely used questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, and the total score was 96 points (Minimum: 0 points; Maximum: 96 points). The question content was divided into three parts: Pain (20 points), Stiffness (8 points), and Physical function (68 points). The higher score meant worse knee joint function. Record the points that the subjects got.

  From the start to the end of treatment at 12 weeks

Other Outcomes (29)

• Concentration change of aspartate aminotransferase (AST)

  From the start to the end of treatment at 12 weeks

• Concentration change of alanine aminotransferase (ALT)

  From the start to the end of treatment at 12 weeks

• Concentration change of blood glucose

  From the start to the end of treatment at 12 weeks

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Placebo use contents without active ingredients

Dietary Supplement: Placebo

A+HA premium oral hyaluronic acid drink

EXPERIMENTAL

A+HA premium oral hyaluronic acid drink contains hyaluronic acid, glucosamine hydrochloride, and chondroitin

Dietary Supplement: A+HA premium oral hyaluronic acid drink

Interventions

Placebo DIETARY_SUPPLEMENT

1 drink daily

Placebo

A+HA premium oral hyaluronic acid drink DIETARY_SUPPLEMENT

1 drink daily

A+HA premium oral hyaluronic acid drink

Eligibility Criteria

• Age: 45 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 45 to 80 years.
• Knee osteoarthritis classified as Ahlbäck stage I or II, or Kellgren-Lawrence grade \<3.
• A Visual Analogue Scale (VAS) pain score ≤3.
• A Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score \>2 or a total WOMAC score \>12.

You may not qualify if:

• Pregnant or breastfeeding women.
• Individuals with a history of knee joint trauma or surgery.
• A body mass index (BMI) ≥ 40 kg/m².
• Individuals with a psychiatric disorder.
• Individuals with severe cardiovascular disease, severe cerebrovascular disease, severe rheumatic disease, crystal deposition arthropathy, or cancer.
• Individuals who use a wheelchair and have a Manual Muscle Testing (MMT) grade ≤3 in the lower extremities, or who require a wheelchair due to physical discomfort.
• Use of anti-inflammatory analgesics, corticosteroids, or other medications that may affect the study outcomes within one week before the trial.
• Receipt of intra-articular corticosteroid injections, hyaluronic acid injections, platelet-rich plasma (PRP) therapy, or nerve block treatment within one month before the trial.
• Use of medications or consumption of foods that, in the judgment of a physician or dietitian, may affect the outcome measures.
• Any other condition considered by the physician to make the individual unsuitable for participation in the trial.

Sponsors & Collaborators

• Taipei Medical University: lead
• Z-Plus Biotechnology Co., Ltd.: collaborator

Study Sites (1)

Taipei Medical University

Taipei, Taiwan

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, CARE PROVIDER
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 12, 2026
• First Posted: September 2, 2026
• Study Start: September 1, 2026
• Primary Completion (Estimated): January 31, 2027
• Study Completion (Estimated): February 28, 2027
• Last Updated: September 2, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)